


PHARMACEUTICAL 2017

Novan Inc. Rank 257 of 313







PHARMACEUTICAL 2017

Novan Inc. Rank 257 of 313



The relative strengths and weaknesses of Novan Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Novan Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 165% points. The greatest weakness of Novan Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 297% points.

The company's Economic Capital Ratio, given in the ranking table, is -564%, being 147% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	35,569
Cost of Goods Sold	0
Intangible Assets	75
Liabilities, Current	13,377
Liabilities, Non-Current	0
Other Assets	539
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	8,030
Other Net Income	127
Property and Equipment	16,290
Research and Development	46,489
Revenues	0
Selling, General and Administrative Expense	13,337

Output Variable	Value in 1000 USD
Assets	52,473
Liabilities	21,407
Expenses	59,826
Stockholders Equity	31,066
Net Income	-59,699
Comprehensive Net Income	-59,699
Economic Capital Ratio	-564%